Skip to content

Study · Not a test of the peptide alone · 2020

1 result

Peptide Ligation at High Dilution via Reductive Diselenide-Selenoester Ligation.

Chisholm TS, Kulkarni SS, Hossain KR, Cornelius F, Clarke RJ, Payne RJ

Journal of the American Chemical Society31 Dec 2019Cited by 55 (Europe PMC)

PMID31840988 (opens in a new tab)DOI10.1021/jacs.9b12558 (opens in a new tab)PepBankPUB-31840988
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Tesamorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Tesamorelin.

  1. 01LabNot a test of Tesamorelin aloneIn vitro (cell-free)Other

    A reductive diselenide-selenoester ligation (rDSL) method allowed efficient chemical synthesis of the lipopeptide tesamorelin.

    In plain wordsIn lab tests, a new peptide joining method made the drug tesamorelin efficiently.

    Peptide
    Tesamorelin
    Outcome
    Not applicableSynthesis of tesamorelin by reductive diselenide-selenoester ligation
    Study

    n: not reported in source

    Outcome group
    Synthesis and manufacturing · Pharmacology

    Source sentences

    Summary
    Herein we describe the advent of a reductive diselenide-selenoester ligation (rDSL) method that enables efficient ligation of peptide fragments down to low nanomolar concentrations, without resorting to solubility tags or hybridizing templates.
    1 context sentence
    Summary · context
    The power of rDSL is highlighted in the efficient synthesis of the FDA-approved therapeutic lipopeptide tesamorelin and palmitylated variants of the transmembrane lipoprotein phospholemman (FXYD1).

    In this study, Tesamorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesamorelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.